Accepted for Publication: June 24, 2011.
Published Online: October 10, 2011. doi:10.1001/archinternmed.2011.502
Author Contributions:Study concept and design: Weinger. Acquisition of data: Weinger, Sitnokov, Ganda, and Caballero. Analysis and interpretation of data: Weinger, Beverly, Lee, Ganda, and Caballero. Drafting of the manuscript: Weinger. Critical revision of the manuscript for important intellectual content: Weinger, Beverly, Lee, Sitnokov, Ganda, and Caballero. Statistical analysis: Weinger and Lee. Obtained funding: Weinger. Administrative, technical, and material support: Weinger, Beverly, Sitnokov, Ganda, and Caballero. Study supervision: Weinger, Ganda, and Caballero.
Financial Disclosure: Dr Caballero serves on the advisory panels of Eli Lilly and Company, Amylin Pharmaceuticals Inc, Takeda Pharmaceuticals America Inc, sanofi-aventis, and Daiichi-Sankyo.
Funding/Support: This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant R01 DK60115 (K.W.), the Diabetes and Endocrinology Research Core grant NIH P30 DK36836, and the Joslin Diabetes Center Clinical Research Center. Abbott Laboratories, Abbott Park, Illinois; LifeScan, Milpitas, California; and Roche Diagnostics, Indianapolis, Indiana, contributed glucose meters and test strips.
Role of the Sponsors: The sponsors had no role in the conduct of the study or preparation of this manuscript.
Previous Presentation: A portion of this report was presented at the American Association of Diabetes Educators Annual Meeting; August 6-9, 2008; Washington, DC.
Additional Contributions: We thank the patients who participated in the study and the nurses and staff at the Joslin Clinical Research Center.